Octadecylamine-Mediated Versatile Coating of CoFe2O4 NPs for the Sustained Release of Anti-Inflammatory Drug Naproxen and in Vivo Target Selectivity
Source abstract
Abstract
Magnetic nanoparticles (MNPs) can play a distinct role in magnetic drug delivery via their distribution to the targeted area. The preparation of such MNPs is a challenging multiplex task that requires the optimization of size, magnetic, and surface properties for the achievement of desirable target selectivity, along with the sustained drug release as a prerequisite. In that context, CoFe2O4 MNPs with a small size of ∼7 nm and moderate saturation magnetization of ∼60 emu g(-1) were solvothermally synthesized in the presence of octadecylamine (ODA) with a view to investigate the functionalization route effect on the drug release. Synthetic regulations allowed us to prepare MNPs with aminated (AmMNPs) and amine-free (FAmMNPs) surface. The addition of the nonsteroidal anti-inflammatory drug with a carboxylate donor, Naproxen (NAP), was achieved by direct coupling with the NH2 groups, rendered by ODA, through the formation of an amide bond in the case of AmMNPs. In the case of FAmMNPs, indirect coupling of NAP was performed through an intermediate linker (polyethylenimine) and on PEG-ylated MNPs. FT-IR, (1)H NMR, (13)C NMR, and UV-vis data confirmed the addition of NAP, whereas diverse drug-release behavior was observed for the different functionalization approaches. The biological behavior of the MNPs@NAP was evaluated in vitro in rat serum and in vivo in mice, after radiolabeling with a γ-emitting radionuclide, (99m)Tc. The in vivo fate of MNPs@NAP carriers was in straightforward relation with the direct or indirect coupling of NAP. Furthermore, an inflammation was induced intramuscularly, where the directly coupled (99m)Tc-MNPs@NAP carriers showed increased accumulation at the inflammation site.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Advanced Drug Delivery Systems · Nanomaterials for catalytic reactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
Department of Pharmaceutical Chemistry, School of Pharmacy, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
Department of Physics, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
Funding
General Secretariat for Research and Technology · European Social Fund
References (57)
Show source-provided references
1. 10.1016/j.saa.2014.02.13510.1016/j.saa.2014.02.135 ↗
2. Uludağ M. O. · Turk. J. Chem. · 2011 · 35 · 427
3. 10.1016/j.jmmm.2008.05.02310.1016/j.jmmm.2008.05.023 ↗
4. 10.1038/ncomms372910.1038/ncomms3729 ↗
5. 10.1021/am507689a10.1021/am507689a ↗
6. 10.1021/cm903837g10.1021/cm903837g ↗
7. 10.1002/smll.20070059510.1002/smll.200700595 ↗
8. 10.1016/j.addr.2009.11.00210.1016/j.addr.2009.11.002 ↗
9. 10.1002/cnma.20150003610.1002/cnma.201500036 ↗
10. 10.1016/j.carbpol.2014.04.01710.1016/j.carbpol.2014.04.017 ↗
11. 10.1002/cmmi.153010.1002/cmmi.1530 ↗
12. 10.2967/jnumed.111.09243710.2967/jnumed.111.092437 ↗
13. 10.1038/nbt134010.1038/nbt1340 ↗
14. 10.1002/ejic.20140232310.1002/ejic.201402323 ↗
15. Belagali S. L. · Indian J. Chem. · 1999 · 38 · 505
16. 10.1016/j.biomaterials.2010.11.04010.1016/j.biomaterials.2010.11.040 ↗
17. 10.1111/j.1423-0410.1979.tb02314.x10.1111/j.1423-0410.1979.tb02314.x ↗
18. 10.1021/bm401128r10.1021/bm401128r ↗
19. 10.1016/0168-3659(87)90034-410.1016/0168-3659(87)90034-4 ↗
20. 10.1016/0168-3659(87)90035-610.1016/0168-3659(87)90035-6 ↗
21. 10.1016/0378-5173(89)90306-210.1016/0378-5173(89)90306-2 ↗
22. 10.1088/0957-4484/25/2/02510110.1088/0957-4484/25/2/025101 ↗
23. 10.1039/c3dt53179a10.1039/c3dt53179a ↗
24. 10.1016/j.partic.2011.11.01210.1016/j.partic.2011.11.012 ↗
25. 10.1021/ic200485v10.1021/ic200485v ↗
26. 10.1021/acs.jpcc.5b0071710.1021/acs.jpcc.5b00717 ↗
27. 10.1166/jnn.2009.NS6010.1166/jnn.2009.NS60 ↗
28. 10.1021/cm303352r10.1021/cm303352r ↗
29. 10.1063/1.174466210.1063/1.1744662 ↗
30. 10.1039/C3OB41971A10.1039/C3OB41971A ↗
31. 10.1021/la981001w10.1021/la981001w ↗
32. 10.1021/la00003a02410.1021/la00003a024 ↗
33. 10.1021/la063255k10.1021/la063255k ↗
34. 10.1016/j.materresbull.2013.04.06710.1016/j.materresbull.2013.04.067 ↗
35. 10.1016/j.jmmm.2011.10.01710.1016/j.jmmm.2011.10.017 ↗
36. 10.1021/ja035474n10.1021/ja035474n ↗
37. 10.1002/chem.20080251310.1002/chem.200802513 ↗
38. 10.1016/j.inoche.2014.03.03910.1016/j.inoche.2014.03.039 ↗
39. 10.1080/00958972.2011.65420310.1080/00958972.2011.654203 ↗
40. 10.1016/S0169-409X(01)00202-210.1016/S0169-409X(01)00202-2 ↗
41. 10.1021/la052990d10.1021/la052990d ↗
42. 10.1038/nmat244210.1038/nmat2442 ↗
43. 10.1021/nl072292910.1021/nl0722929 ↗
44. Marszałł M. P. · 2012 · 100
45. 10.1039/b820176e10.1039/b820176e ↗
46. Singhvi G. · Int. J. Pharm. Stud. Res. · 2011 · 2 · 77
47. 10.1155/2015/19817510.1155/2015/198175 ↗
48. 10.1039/C5TB02045J10.1039/C5TB02045J ↗
49. 10.1039/C4TB01367K10.1039/C4TB01367K ↗
50. 10.1002/jlcr.309710.1002/jlcr.3097 ↗
51. 10.1016/j.ijpharm.2004.09.02210.1016/j.ijpharm.2004.09.022 ↗
52. 10.1016/j.ejpb.2007.08.00110.1016/j.ejpb.2007.08.001 ↗
53. 10.1016/j.nano.2010.05.00210.1016/j.nano.2010.05.002 ↗
54. Zuckier L. S. · J. Nucl. Med. · 2004 · 45 · 500
55. 10.1016/j.pain.2006.09.03810.1016/j.pain.2006.09.038 ↗
56. Oyen W. J. · J. Nucl. Med. · 1996 · 37 · 1392
57. 10.1002/art.178021031010.1002/art.1780210310 ↗